More infections from contaminated eyedrops increase death toll
James Spargo | May 23, 2023 | News story | Medical Communications | FDA, Opthalmology, eyedrops, infections
The US Centers for Disease Control and Prevention (CDC) have released updated data regarding contaminated eyedrops. As of May 2023, 81 patients in 18 states have tested positive for VIM-GES-CRPA, a rare strain of drug-resistant P. aeruginosa.
In February 2023, 55 reports of eye infections, permanent vision loss and one death led to the US Food and Drug Administration (FDA) issuing a recall for EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears. The FDA then investigated Global Pharma’s manufacturing plant in Chennai city, India, where it discovered several violations.
Some of these violations included failure to provide adequate, tamper-evident packaging, and the distribution of drugs without correct preservatives. The CDC confirmed a matching strain of P. aeruginosa in opened bottles to the one found in specimens taken from patients.
In March 2023 the CDC revealed 68 patients had been infected, eight people had vision loss, four underwent enucleation (surgical removal of the eyeball) and three people had died. As of May 2023, 14 people have suffered vision loss and four people have died.
The CDC recommends purchasers and prescribers of the eye drops to “immediately stop using and discard EzriCare Artifical Tears, Delsam Pharma Artifical Tears and Delsam Pharma Artificial Ointment.” The FDA has asked “health professionals and patients to report adverse events or quality problems with any medicine to FDA’s MedWatch Adverse Event Reporting programme.”
James Spargo
Related Content
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
MedPharm announces US FDA inspection of North Carolina manufacturing facility
MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
